JAHA:儿童期癌症长期幸存者心衰的发展和表型情况

2023-10-01 MedSci原创 MedSci原创 发表于陕西省

与人群相比,长期CCSs中A至D期心衰的患病率明显更高,并且因肿瘤实体而有很大差异。收缩功能障碍主要与肿瘤实体相关,而舒张功能障碍与CCSs中较高的心血管危险因素负担相关。

在过去的几十年里,癌症治疗的发展使儿童癌症患者的生存率显著提高,5年生存率几乎达到80%。然而,生存率的提高与严重和危及生命的治疗相关影响的风险增加以及较高的晚期死亡率相关。虽然最近的研究结果表明,与较旧的治疗方案相比,由于化疗药物累积剂量的减少,晚期死亡率有所下降,但心血管并发症对死亡率的影响仍然很大,是造成超额死亡的最大非恶性因素。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,儿童癌症长期幸存者的心脏和血管晚期后遗症(CVSS)研究旨在调查儿童癌症幸存者(CCSs)与普通人群相比不同阶段心力衰竭(HF)的患病率。

1002例15岁前诊断为肿瘤的CCSs(年龄范围为23-48岁)接受了全面的心血管筛查。从以人口为基础的古登堡健康研究(GHS)中选取年龄和性别匹配的样本作为对照组。

虽然心衰的患病率在CCSs中明显较高,但不同阶段的心衰患病率因特定的肿瘤病史而有很大差异。与人群相比,在年龄和性别调整的泊松回归模型中,A期心衰的患病率为2.6 (95%CI为2.4-2.8),B至D期心衰综合的患病率为4.6 (95%CI为4.1-5.1)。多变量线性回归,调整肿瘤实体、年龄、性别和心血管危险因素,显示骨肿瘤(β为-4.30 [95%CI为- 5.70至- 2.80])、软组织肉瘤(β为-1.60 [95%CI为- 2.90至- 0.30])和肾肿瘤(β为-1.60 [95%CI为- 2.80至- 0.29])患者的左心室射血分数较人群低。舒张标志的相同模型,即舒张早期充盈速度/侧二尖瓣早期舒张速度之比,显示仅与心血管危险因素相关,而与肿瘤实体无关。

由此可见,与人群相比,长期CCSs中A至D期心衰的患病率明显更高,并且因肿瘤实体而有很大差异。收缩功能障碍主要与肿瘤实体相关,而舒张功能障碍与CCSs中较高的心血管危险因素负担相关。

原始出处:

Sebastian Göbel,et al.Development and Phenotype of Heart Failure in Long‐Term Survivors of Childhood Cancer: The CVSS Study.JAHA.2023.https://www.ahajournals.org/doi/10.1161/JAHA.123.030020

相关资料下载:
[AttachmentFileName(sort=1, fileName=Development and Phenotype of Heart Failure in Long‐Term Survivors of Childhood Cancer_ The CVSS Study.pdf)] GetArticleByIdResponse(id=5aa1e94241c3, projectId=1, sourceId=null, title=JAHA:儿童期癌症长期幸存者心衰的发展和表型情况, articleFrom=MedSci原创, journalId=12278, copyright=原创, creationTypeList=[1], summary=与人群相比,长期CCSs中A至D期心衰的患病率明显更高,并且因肿瘤实体而有很大差异。收缩功能障碍主要与肿瘤实体相关,而舒张功能障碍与CCSs中较高的心血管危险因素负担相关。, cover=https://img.medsci.cn/20230930/1696039799100_1739456.jpg, authorId=0, author=, originalUrl=, linkOutUrl=, content=<p>在过去的几十年里,癌症治疗的发展使儿童癌症患者的生存率显著提高,5年生存率几乎达到80%。然而,生存率的提高与严重和危及生命的治疗相关影响的风险增加以及较高的晚期死亡率相关。虽然最近的研究结果表明,与较旧的治疗方案相比,由于化疗药物累积剂量的减少,晚期死亡率有所下降,但心<a href="https://www.medsci.cn/guideline/list.do?q=%E8%A1%80%E7%AE%A1">血管</a>并发症对死亡率的影响仍然很大,是造成超额死亡的最大非恶性因素。</p> <p>近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,儿童癌症长期幸存者的心脏和血管晚期后遗症(CVSS)研究旨在调查儿童癌症幸存者(CCSs)与普通人群相比不同阶段心力衰竭(HF)的患病率。</p> <p><img style="display: block; margin-left: auto; margin-right: auto;" src="https://img.medsci.cn/20230930/1696039861662_1739456.png" width="450" /></p> <p>1002例15岁前<a href="https://www.medsci.cn/guideline/list.do?q=%E8%AF%8A%E6%96%AD">诊断</a>为肿瘤的CCSs(年龄范围为23-48岁)接受了全面的心血管<a href="https://www.medsci.cn/search?q=%E7%AD%9B%E6%9F%A5">筛查</a>。从以人口为基础的古登堡健康研究(GHS)中选取年龄和性别匹配的样本作为对照组。</p> <p><img style="display: block; margin-left: auto; margin-right: auto;" src="https://img.medsci.cn/20230930/1696039861670_1739456.png" width="450" /></p> <p>虽然<a href="https://www.medsci.cn/search?q=%E5%BF%83%E8%A1%B0">心衰</a>的患病率在CCSs中明显较高,但不同阶段的心衰患病率因特定的肿瘤病史而有很大差异。与人群相比,在年龄和性别调整的泊松回归模型中,A期心衰的患病率为2.6 (95%CI为2.4-2.8),B至D期心衰综合的患病率为4.6 (95%CI为4.1-5.1)。多变量线性回归,调整肿瘤实体、年龄、性别和心血管危险因素,显示骨肿瘤(&beta;为-4.30 [95%CI为- 5.70至- 2.80])、软组织肉瘤(&beta;为-1.60 [95%CI为- 2.90至- 0.30])和肾肿瘤(&beta;为-1.60 [95%CI为- 2.80至- 0.29])患者的左心室射血分数较人群低。舒张标志的相同模型,即舒张早期充盈速度/侧二尖瓣早期舒张速度之比,显示仅与心血管危险因素相关,而与肿瘤实体无关。</p> <p>由此可见,<strong>与人群相比,长期CCSs中A至D期心衰的患病率明显更高,并且因肿瘤实体而有很大差异。收缩功能障碍主要与肿瘤实体相关,而舒张功能障碍与CCSs中较高的心血管危险因素负担相关。</strong></p> <p><span style="font-size: 12px; color: #808080;">原始出处:</span></p> <p><span style="font-size: 12px; color: #808080;">Sebastian G&ouml;bel,et al.Development and Phenotype of Heart Failure in Long‐Term Survivors of Childhood Cancer: The CVSS Study.JAHA.2023.https://www.ahajournals.org/doi/10.1161/JAHA.123.030020</span></p>, belongTo=, tagList=[TagDto(tagId=448, tagName=心衰), TagDto(tagId=1081, tagName=表型), TagDto(tagId=480803, tagName=儿童期癌症长期幸存者)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=84, categoryName=研究进展, tenant=100), CategoryDto(categoryId=20656, categoryName=梅斯医学, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, opened=1, paymentType=1, paymentAmount=0, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3218, appHits=14, showAppHits=0, pcHits=61, showPcHits=3204, likes=0, shares=7, comments=4, approvalStatus=1, publishedTime=Sun Oct 01 16:14:00 CST 2023, publishedTimeString=2023-10-01, pcVisible=1, appVisible=1, editorId=6529998, editor=心血管新前沿, waterMark=0, formatted=0, deleted=0, version=3, createdBy=c5bb1739456, createdName=xing.T, createdTime=Sat Sep 30 10:11:54 CST 2023, updatedBy=92910, updatedName=rayms, updatedTime=Sat Jan 06 20:58:03 CST 2024, ipAttribution=陕西省, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=Development and Phenotype of Heart Failure in Long‐Term Survivors of Childhood Cancer_ The CVSS Study.pdf)], guideDownload=1)
Development and Phenotype of Heart Failure in Long‐Term Survivors of Childhood Cancer_ The CVSS Study.pdf
版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2160598, encodeId=44842160598c5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Oct 02 08:32:26 CST 2023, time=2023-10-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2160580, encodeId=926f216058075, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 02 00:14:30 CST 2023, time=2023-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2160551, encodeId=ebcd2160551bb, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Oct 01 18:32:27 CST 2023, time=2023-10-01, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160548, encodeId=34a821605487c, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00332233446, createdName=1212ad1cm87暂无昵称, createdTime=Sun Oct 01 17:57:00 CST 2023, time=2023-10-01, status=1, ipAttribution=吉林省)]
    2023-10-02 1209e435m98(暂无昵称) 来自浙江省

    学习了,谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2160598, encodeId=44842160598c5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Oct 02 08:32:26 CST 2023, time=2023-10-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2160580, encodeId=926f216058075, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 02 00:14:30 CST 2023, time=2023-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2160551, encodeId=ebcd2160551bb, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Oct 01 18:32:27 CST 2023, time=2023-10-01, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160548, encodeId=34a821605487c, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00332233446, createdName=1212ad1cm87暂无昵称, createdTime=Sun Oct 01 17:57:00 CST 2023, time=2023-10-01, status=1, ipAttribution=吉林省)]
    2023-10-02 仁术2021 来自吉林省

    不错,学习了。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2160598, encodeId=44842160598c5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Oct 02 08:32:26 CST 2023, time=2023-10-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2160580, encodeId=926f216058075, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 02 00:14:30 CST 2023, time=2023-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2160551, encodeId=ebcd2160551bb, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Oct 01 18:32:27 CST 2023, time=2023-10-01, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160548, encodeId=34a821605487c, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00332233446, createdName=1212ad1cm87暂无昵称, createdTime=Sun Oct 01 17:57:00 CST 2023, time=2023-10-01, status=1, ipAttribution=吉林省)]
    2023-10-01 医鸣惊人 来自山西省

    认真学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2160598, encodeId=44842160598c5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Oct 02 08:32:26 CST 2023, time=2023-10-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2160580, encodeId=926f216058075, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Oct 02 00:14:30 CST 2023, time=2023-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2160551, encodeId=ebcd2160551bb, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Sun Oct 01 18:32:27 CST 2023, time=2023-10-01, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160548, encodeId=34a821605487c, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00332233446, createdName=1212ad1cm87暂无昵称, createdTime=Sun Oct 01 17:57:00 CST 2023, time=2023-10-01, status=1, ipAttribution=吉林省)]
    2023-10-01 1212ad1cm87暂无昵称 来自吉林省

    不错,学习了。

    0

相关资讯

Eur J Heart Fail:中性粒细胞载脂蛋白与心衰和心功能障碍相关

与中性粒细胞功能相关的血浆蛋白与中老年心力衰竭事件和不良心脏重构相关。调整这些蛋白的疗法,如秋水仙碱,可能是预防或治疗心衰有前景的靶点。

ESC 2023 中国之声 | 传统中药「芪苈强心胶囊」为心衰治疗提供新证据(QUEST 研究)

传统中药芪苈强心胶囊能够显著降低心衰患者心血管死亡率和心衰再住院率,这意味着芪苈强心胶囊能在标准药物治疗基础上给HFrEF患者带来更多获益。

NEJM:羧基麦芽糖铁与缺铁心衰的关系

在心力衰竭患者中,缺铁是常见的,在射血分数降低和缺铁的心力衰竭患者中,在死亡、心力衰竭住院或6分钟步行距离方面,羧基麦芽糖铁治疗组与安慰剂组之间没有观察到明显差异。

樊晓寒教授团队解读BUDAPEST CRT Upgrade临床研究结果:高右室起搏比例、宽起搏QRS波的心衰患者应升级CRT

2023年欧洲心脏病学会年会(ESC 2023)于8月25日-28日在荷兰阿姆斯特丹以线上线下相结合的方式举办。中国医学论坛报今日循环将持续为各位报道ESC 2023最新资讯。

ESC 2023 :HFpEF合并肥胖患者每周一次司美格鲁肽,不仅能减轻体重,还能能更大程度地减轻心衰症状和身体限制(STEP-HFpEF 研究)

对于HFpEF肥胖患者来说,与安慰剂相比,服用司美格鲁肽(2.4毫克)治疗能更大程度地减轻心衰症状和身体限制,改善运动功能,减轻体重。

ESC 2023 重磅研究:「羧基麦芽糖铁」治疗HFrEF合并缺铁的心衰试验未达到主要终点(HEART-FID研究)

HEART-FID试验证实了静脉注射FCM对HFrEF合并缺铁患者的安全性,尽管提示了潜在的疗效,但并未达到主要疗效终点。